Study to support differentiated efficacy of Vendaje® structural tissue allograft POMPANO BEACH, FLORIDA, October 24, 2023 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, today announced that the first site is now fully opened for its clinical trial, evaluating the Vendaje® tissue allograft in the treatment of diabetic foot ulcers (DFU). Jason...
![BioStem Technologies Announces Opening of First Clinical Site for Diabetic Foot Ulcer Study](https://prismmediawire.com/wp-content/uploads/2023/10/BioStem-Technologies-Announces-Opening-of-First-Clinical-Site-for-Diabetic-Foot-Ulcer-Study-1080x675.png)